1095010-50-6

Basic information

• Product Name: 2-bromo-4-cyclopropylthiazole
• Synonyms: 2-bromo-4-cyclopropylthiazole
• CAS NO: 1095010-50-6
• Molecular Formula: C6H6BrNS
• Molecular Weight: 204.08754
• Mol File: 1095010-50-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 255.4±9.0 °C(Predicted)
• Appearance: /
• Density: 1.754±0.06 g/cm3(Predicted)
• PKA: 1.17±0.10(Predicted)
• CAS DataBase Reference: 2-bromo-4-cyclopropylthiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4-cyclopropylthiazole(1095010-50-6)
• EPA Substance Registry System: 2-bromo-4-cyclopropylthiazole(1095010-50-6)

Safety Data

• Hazardous Substances Data: 1095010-50-6(Hazardous Substances Data)

Usage

General Description

2-bromo-4-cyclopropylthiazole is a chemical compound with the molecular formula C6H6BrNS. It is a thiazole derivative with a bromine atom and a cyclopropyl group attached to the thiazole ring. 2-bromo-4-cyclopropylthiazole has potential applications in the field of medicinal chemistry, as thiazole derivatives have been studied for their biological activities such as antimicrobial, antitubercular, and anticancer properties. Additionally, the presence of the cyclopropyl group in 2-bromo-4-cyclopropylthiazole may confer unique chemical and pharmacological properties. Further research is needed to fully understand the potential applications and properties of this compound.

Upstream product

• 324579-90-0 2-amino-4-cyclopropylthiazole 
• 69267-75-0 2-bromo-1-cyclopropylethan-1-one 

Downstream Products

• 1378765-88-8 C₇H₆N₂S 
• 1578154-93-4 (3S)-4-[[(4R)-4-(2-chloro-4-fluoro-phenyl)-2-(4-cyclopropylthiazol-2-yl)-5-methoxycarbonyl-1,4-dihydropyrimidin-6-yl]methyl]-morpholine-3-carboxylic acid 

Relevant articles and documents

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula:, wherein R1, R2, R3, R4 and A are as described herein, compositions including the compounds and methods of using the compounds.